| Field Name |
Format |
Description |
| PATIENT | Character or Numeric | *Required Code to identify patient (Cohort Patient ID) |
| ART_ID | Character
See Code ListART_ID | Code | Definition | | J05A | ART unspecified | | J05A-BEV | Beviramat | | J05A-PBT | Participant in Blinded Trial | | J05AE | PI unspecified | | J05AE-MOZ | Mozenavir (DMP-450) | | J05AE01 | Saquinavir (gel, not specified) | | J05AE01-SQH | Saquinavir hard gel (INVIRASE) | | J05AE01-SQS | Saquinavir soft gel (FORTOVASE) | | J05AE02 | Indinavir (CRIXIVAN) | | J05AE03 | Ritonavir (NORVIR) | | J05AE03-H | Ritonavir high dose (NORVIR) | | J05AE03-L | Ritonavir low dose (NORVIR) | | J05AE04 | Nelfinavir (VIRACEPT) | | J05AE05 | Amprenavir (AGENERASE) | | J05AR10 | Lopinavir/Ritonavir (Kaletra). Former code: J05AE06 | | J05AE07 | Fos-amprenavir (Telzir, Lexiva) | | J05AE08 | Atazanavir (Reyataz) | | J05AE09 | Tipranavir (Aptivus) | | J05AE10 | Darunavir (TMC-114, Prezista) | | J05AF | NRTI unspecified | | J05AF-ALO | Alovudine | | J05AF-AMD | Amdoxovir (DADP) | | J05AF-FOZ | Fozivudine tidoxi | | J05AF-LDN | Lodenosine (trial drug) | | J05AF-RVT | Reverset | | J05AF01 | Zidovudine (AZT, RETROVIR) | | J05AF02 | Didanosine (ddI) (VIDEX) | | J05AF03 | Zalcitabine (ddC) (HIVID) | | J05AF04 | Stavudine (d4T) (ZERIT) | | J05AF05 | Lamivudine (3TC, EPIVIR) | | J05AF06 | Abacavir (1592U89) (ZIAGEN) | | J05AF07 | Tenofovir (VIREAD) | | J05AF08 | Adefovir (PREVEON) | | J05AF09 | Emtricitabine | | J05AF10 | Entecavir | | J05AF11 | Telbivudine | | J05AF13 | tenofovir alafenamide | | J05AG | NNRTI unspecified | | J05AG-BIC | Bictegravir | | J05AG-CPV | Capravirine | | J05AG-DPC083 | DPC 083 | | J05AG-DPC961 | DPC 961 | | J05AG-EMV | Emivirine (MKC442) | | J05AG04 | Etravirine (TMC 125). Former code: J05AG-ETV | | J05AG-LOV | Loviride | | J05AG05 | Rilpivirine (TMC-278). Former code: J05AG-RPV | | J05AG01 | Nevirapine (VIRAMUN) | | J05AG02 | Delavirdine (U-90152) (RESCRIPTOR) | | J05AG03 | Efavirenz (DMP-266) (STOCRIN, SUSTIVA) | | J05AG06 | Doravirine | | J05AJ01 | raltegravir | | J05AJ02 | Elvitegravir (former code: J05AX11) | | J05AJ03 | dolutegravir | | J05AJ04 | Cabotegravir | | J05AR01 | Combivir (Zidovudine/Lamivudine) | | J05AR02 | Kivexa (Lamivudine/Abacavir) | | J05AR03 | Truvada (Tenofovir/Emtricabine) | | J05AR04 | Trizivir (Zidovudine/Lamivudine/Abacavir) | | J05AR05 | Douvir-N (Zidovudine/Lamivudine/Nevirapine) | | J05AR06 | Atripla (Emtricitabine/Tenofovir/Efavirenz) | | J05AR07 | Triomune (Stavudine/Lamivudine/Nevirapine) | | J05AR08 | Eviplera/Complera (Emtricitabine/Tenofovir/Rilpivirine) | | J05AR09 | Stribild (Emtricitabine/Tenofovir/Elvitegravir/Cobicistat) | | J05AR10 | Kaletra/Aluvia (Lopinavir/Ritonavir) | | J05AR11 | Lamivudine, tenofovir disoproxil and efavirenz | | J05AR12 | Lamivudine and tenofovir disoproxil | | J05AR13 | Lamivudine, abacavir and dolutegravir | | J05AR14 | Darunavir and cobicistat | | J05AR15 | (Evotaz) atazanavir and cobicistat | | J05AR16 | lamivudine and raltegravir | | J05AR17 | emtricitabine and tenofovir alafenamide | | J05AR18 | emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat | | J05AR19 | emtricitabine, tenofovir alafenamide and rilpivirine | | J05AR20 | emtricitabine, tenofovir alafenamide and bictegravir | | J05AR21 | dolutegravir and rilpivirine | | J05AR22 | emtricitabine, tenofovir alafenamide, darunavir and cobicistat | | J05AR23 | Atazanavir and ritonavir | | J05AR24 | lamivudine, tenofovir disoproxil and doravirine | | J05AR25 | lamivudine and dolutegravir | | J05AR26 | Darunavir and ritonavir | | J05AR27 | lamivudine, tenofovir disoproxil and dolutegravir | | J05AR30 | Tenofir and emtricitabine | | J05AX11 | Elvitegravir (Gilead). (deprecated; replaced by J05AJ02) | | J05AX-VIC | Vicriviroc (Schering) | | J05AX07 | Enfurvirtide (Fuzeon , T-20) | | J05AX08 | Raltegravir (deprecated; replaced by J05AJ01) | | J05AX09 | Maraviroc (Pfizer) | | J05AX12 | Dolutegravir (deprecated; replaced by J05AJ03) | | J05AX29 | fostemsavir | | J05AX-CAB | Cabotegravir (GSK-744) (deprecated, replaced by J05AJ04) | | L01XX05 | Hydroxyurea/Hydroxycarbamid (Litalir) | | V03AX03 | Cobicistat |
| *Required ATC code for the patient's ARV medication Codes are drawn from the Anatomical Therapeutic Chemical (ATC) classification system. The list provided here includes most relevant drugs. A searchable index is available at http://www.whocc.no/atc_ddd_index/ |
| ART_SD | YYYY-MM-DD | *Required Date of initiation of treatment |
| ART_SD_A | Character < = Before this date
D = Exact to the date
M = Exact to the month
Y = Exact to the year
> = After the date
U = Unknown
| Date approximation for ART_SD |
| ART_ED | YYYY-MM-DD | Date of stopping of treatment |
| ART_ED_A | Character < = Before this date
D = Exact to the date
M = Exact to the month
Y = Exact to the year
> = After the date
U = Unknown
| Date approximation for ART_ED |
| ART_RS | Character
See Code ListART_RS | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Reason for stopping treatment |
| ART_RS2 | Character
See Code ListART_RS2 | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Additional reason for stopping treatment Uses same list of codes as ART_RS |
| ART_RS3 | Character
See Code ListART_RS3 | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Additional reason for stopping treatment Uses same list of codes as ART_RS |
| ART_RS4 | Character
See Code ListART_RS4 | Code | Definition | | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | | 1.1 | Virological failure | | 1.2 | Partial virological failure | | 1.3 | Immunological failure - CD4 drop | | 1.4 | Clinical progression | | 1.5 | Resistance (based on test result) | | 2 | Abnormal fat redistribution | | 3 | Concern of cardiovascular disease | | 3.1 | Dyslipidaemia | | 3.2 | Cardiovascular disease | | 4 | Hypersensitivity reaction | | 5 | Toxicity, predominantly from abdomen/G-I tract | | 5.1 | Toxicity - GI tract | | 5.2 | Toxicity - Liver | | 5.3 | Toxicity - Pancreas | | 6 | Toxicity, predominantly from nervous system | | 6.1 | Toxicity - peripheral neuropathy | | 6.2 | Toxicity - neuropsychiatric | | 6.3 | Toxicity - headache | | 7 | Toxicity, predominantly from kidneys | | 8 | Toxicity, predominantly from endocrine system | | 8.1 | Diabetes | | 9 | Haematological toxicity (anemia, etc.) | | 10 | Hyperlactataemia/lactic acidosis | | 11 | Bone toxicity | | 15 | Social contra-indication | | 16 | Contra-indication unspecified | | 16.8 | Contra-indication expired | | 16.9 | Contra-indication - other | | 17 | MTCT regimen completed | | 70 | Pregnancy - toxicity concerns (during pregnancy) | | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | | 88 | Death | | 90 | Side effect - any of the above not mentioned | | 90.1 | Comorbidity | | 91 | Toxicity - other (not mentioned above) | | 91.1 | Toxicity - unspecified | | 92 | More effective treatment available | | 92.1 | Simplified treatment available | | 92.2 | Treatment too complex | | 92.3 | Drug interaction | | 92.31 | Drug interaction - commencing TB/BCG treatment | | 92.32 | Drug interaction - ended TB/BCG treatment | | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | | 92.4 | Protocol change | | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | | 92.6 | End of empiric therapy | | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | | 92.91 | Change to a generic drug | | 92.92 | Change to branded drug | | 93 | Structured Treatment Interruption (STI) | | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | | 94 | Patient's wish/ decision, not specified above | | 94.1 | Non-compliance | | 94.2 | Defaulter | | 95 | Physician's decision, not specified above | | 96 | Pregnancy | | 96.1 | Pregnancy intended | | 96.2 | Pregnancy ended | | 97 | Study treatment | | 97.1 | Study treatment commenced | | 97.2 | Study treatment completed | | 97.6 | Drug not available | | 98 | Other causes, not specified above | | 99 | Unknown |
| Additional reason for stopping treatment Uses same list of codes as ART_RS |
| ART_FORM | Numeric 1 = Tablet/capsule
2 = Syrup/suspension
3 = Combination of 1 and 2
4 = Powder
5 = Subcutaneous
6 = Intravenous
7 = Intramuscular
9 = Unknown
| What formulation of the drug was given? |
| ART_COMB | Numeric 0 = Individual drug
1 = Part of a fixed-dose combination
9 = Unknown
| Was the drug given as part of a fixed-dose combination? |
| ARTSTART_RS | Character 1 = PMTCT
30 = ARV as treatment
40 = PEP, Post Exposure Prophylaxis
50 = PREP
95 = Not ascertained
99 = Unknown despite attempting ascertainment
| Reason for starting/receiving ART |